Sustained levodopa therapy in parkinsonism.
D000203:Activities of Daily Living; D000368:Aged; D003072:Cognition Disorders / Q000139:chemically induced; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005149:Facial Expression; D005260:Female; D005500:Follow-Up Studies; D005684:Gait; D006212:Hallucinations / Q000139:chemically induced; D006801:Humans; D007024:Hypotension, Orthostatic / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D010259:Paranoid Disorders / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy*; D011187:Posture; D013060:Speech; D013375:Substance Withdrawal Syndrome; D013546:Sweating; D013997:Time Factors
D004295:Dihydroxyphenylalanine